Skip to content
★ Sign in to follow
JP

Jeil Pharma Holdings Inc Stock: price and insider trades · South Korea

제일파마홀딩스

KR·Mcap ₩103.2BHealth Care

No insider purchase over the last 90 days. The latest, by 한상철, was filed 15 Jul 2026.

Jeil Pharma Holdings Inc: what insiders have been doing

Jeil Pharma Holdings Inc belongs to the Health Care sector. Filings by its managers are published through DART (FSS). Between 2 November 2025 and 2 November 2026, 3 insiders published 7 filings.

The record shows 3 purchases on the open market, made by 2 insiders, against 2 sales by 1 insider. The amount is not disclosed for 5 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 chief executive.

Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 7 filings, this issuer sits right on that mark. Our records for Jeil Pharma Holdings Inc go back to 2026, with 3 purchases and 2 sales on the open market in total.

The most recent open-market purchase was published on 15 July 2026, 118 days ago.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.

Insider Decl.
7
Thresholds
n/a
Buy Volume
€625,029
3 ops. · all time
Sell Volume
€558,961
2 ops. · all time

Who traded when

BuySale
한승수1 buy2 sales
한상철2 buys

Since the insiders bought

  • Filed 15 Jul 2026 · 118 days ago · €299k
    +12.8%
    Entry ₩6,590 · Close at T+90 ₩7,432
  • Filed 30 Apr 2026 · 194 days ago · €66k
    -23.9%
    Entry ₩8,830 · Close 30 Oct 2026 ₩6,720

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Fundamental score
Ranked 10,736 of 26,911 companies
56.6
score / 100
Value
68
Quality
45
FCF yld-8.6%
Earn yld14%
EV/EBITDA4.4x
ROE5.5%
Gross mgn39%
Net mgn2.2%
Debt/EBITDA2.7x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩6,720
Analyst consensus
·
Income statement
Revenue₩657.6B
Gross profit₩253.5B39% margin
EBITDA₩61.8B9% margin
Net income₩14.6B1.3% margin
Valuation
Beta0.45
Balance sheet & cash
Market cap₩103.2B
Total debt₩167.4B
Free Cash Flow-₩8.9B
Debt / Equity39%
Profitability & ownership
ROE5.5%
ROA1.3%
% insiders82.6%
% institutions0.0%
Last declaration on 15 July 2026
Declarations7 total
  • ●
    Executives
    Executives(filed)
    0DART
  • ▼
    회장Executives(filed)
    €299kest.0DART
    80,000 sharesShareKRXDART:20260715000429
  • ▲
    대표이사Executives(filed)
    €299kest.0DART
    80,000 sharesShareKRXDART:20260715000453
    Canonical exit: 13 Oct 2026 (T+90)
  • ▼
    회장Executives(filed)
    €260kest.0DART
    70,000 sharesShareKRXDART:20260623000299
  • ▲
    대표이사Executives(filed)
    €260kest.0DART
    70,000 sharesShareKRXDART:20260623000271
    Canonical exit: 21 Sept 2026 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    Executives
    €66kest.0DART
    14,469 sharesKRXDART:20260430001619
    Canonical exit: 28 Jul 2026 (T+90)

7 of 7 declarations

About Jeil Pharma Holdings Inc

제일파마홀딩스 is a company listed on the XKRX market, specializing in the healthcare and pharmaceutical sector. It focuses on the development and distribution of pharmaceutical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations